M. Sugimoto

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer

Y. Doki, Keunchil Park, Chih-Hung Hsu, 2022, Cancer medicine.

Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors

G. Vlahović, N. Yamamoto, S. Ueda, 2019, Cancer science.

Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).

Y. Doki, Keunchil Park, M. Ikeda, 2019, Journal of Clinical Oncology.